Page 55 - Read Online
P. 55

Page 12 of 13                                               Yang et al. Hepatoma Res 2020;6:37  I  http://dx.doi.org/10.20517/2394-5079.2020.09

                   of 732 patients with an elevated platelet count. J Intern Med 1999;245:295-300.
               67.  Coppinger JA, Cagney G, Toomey S, Kislinger T, Belton O, et al. Characterization of the proteins released from activated platelets leads
                   to localization of novel platelet proteins in human atherosclerotic lesions. Blood 2004;103:2096-104.
               68.  Ghanima W, Godeau B, Cines DB, Bussel JB. How I treat immune thrombocytopenia: the choice between splenectomy or a medical
                   therapy as a second-line treatment. Blood 2012;120:960-9.
               69.  He S, He F. Predictive model of portal venous system thrombosis in cirrhotic portal hypertensive patients after splenectomy. Int J Clin
                   Exp Med 2015;8:4236-42.
               70.  Wang L, Liu GJ, Chen YX, Dong HP, Zhang YQ, et al. Combined use of D-dimer and P-selectin for the diagnosis of splenic or portal vein
                   thrombosis following splenectomy. Thromb Res 2010;125:e206-9.
               71.  Hirashita T, Ohta M, Kai S, Masuda T, Eguchi H, et al. Implications of portal vein thrombosis after splenectomy for patients with
                   idiopathic portal hypertension. Surg Today 2011;41:1475-80.
               72.  Qi X, De Stefano V, Li H, Dai J, Guo X, et al. Anticoagulation for the treatment of portal vein thrombosis in liver cirrhosis: a systematic
                   review and meta-analysis of observational studies. Eur J Intern Med 2015;26:23-9.
               73.  Bates SM, Grand’Maison A, Johnston M, Naguit I, Kovacs MJ, et al. A latex D-dimer reliably excludes venous thromboembolism. Arch
                   Intern Med 2001;161:447-53.
               74.  Shorr AF, Thomas SJ, Alkins SA, Fitzpatrick TM, Ling GS. D-dimer correlates with proinflammatory cytokine levels and outcomes in
                   critically ill patients. Chest 2002;121:1262-8.
               75.  Kinasewitz GT, Yan SB, Basson B, Comp P, Russell JA, et al. Universal changes in biomarkers of coagulation and inflammation occur in
                   patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569]. Crit Care 2004;8:R82-90.
               76.  Di Sabatino A, Carsetti R, Corazza GR. Post-splenectomy and hyposplenic states. Lancet 2011;378:86-97.
               77.  Levi M, Sivapalaratnam S. Disseminated intravascular coagulation: an update on pathogenesis and diagnosis. Expert Rev Hematol
                   2018;11:663-72.
               78.  Levi M, van der Poll T, ten Cate H, van Deventer SJ. The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms
                   in sepsis and endotoxaemia. Eur J Clin Invest 1997;27:3-9.
               79.  van der Poll T, Levi M, Hack CE, ten Cate H, van Deventer SJ, et al. Elimination of interleukin 6 attenuates coagulation activation in
                   experimental endotoxemia in chimpanzees. J Exp Med 1994;179:1253-9.
               80.  Osterud B, Rao LV, Olsen JO. Induction of tissue factor expression in whole blood: lack of evidence for the presence of tissue factor
                   expression in granulocytes. Thromb Haemost 2000;83:861-7.
               81.  Franco RF, de Jonge E, Dekkers PE, Timmerman JJ, Spek CA, et al. The in vivo kinetics of tissue factor messenger RNA expression
                   during human endotoxemia: relationship with activation of coagulation. Blood 2000;96:554-9.
               82.  Furie B, Furie BC. Role of platelet P-selectin and microparticle PSGL-1 in thrombus formation. Trends Mol Med 2004;10:171-8.
               83.  Campillo B, Richardet JP, Bories PN. Validation of body mass index for the diagnosis of malnutrition in patients with liver cirrhosis.
                   Gastroenterol Clin Biol 2006;30:1137-43.
               84.  Ponziani FR, Zocco MA, Campanale C, Rinninella E, Tortora A, et al. Portal vein thrombosis: insight into physiopathology, diagnosis,
                   and treatment. World J Gastroenterol 2010;16:143-55.
               85.  Amitrano L, Guardascione MA, Brancaccio V, Margaglione M, Manguso F, et al. Risk factors and clinical presentation of portal vein
                   thrombosis in patients with liver cirrhosis. J Hepatol 2004;40:736-41.
               86.  Dentali F, Galli M, Gianni M, Ageno W. Inherited thrombophilic abnormalities and risk of portal vein thrombosis. a meta-analysis.
                   Thromb Haemost 2008;99:675-82.
               87.  Zhou JB, Luo BY, Liu CW, Zhu F. Effects of early antiplatelet therapy after splenectomy with gastro-oesophageal devascularization. ANZ
                   J Surg 2018;88:E725-9.
               88.  Zakko A, Kroner PT, Nankani R, Karagozian R. Obesity is not associated with an increased risk of portal vein thrombosis in cirrhotic
                   patients. Gastroenterol Hepatol Bed Bench 2018;11:153-8.
               89.  Eshraghian A, Nikeghbalian S, Kazemi K, Mansoorian M, Shamsaeefar A, et al. Portal vein thrombosis in patients with liver cirrhosis and
                   its impact on early and long-term outcomes after liver transplantation. Int J Clin Pract 2018;e13309.
               90.  Hu KQ, Yu AS, Tiyyagura L, Redeker AG, Reynolds TB. Hyperfibrinolytic activity in hospitalized cirrhotic patients in a referral liver
                   unit. Am J Gastroenterol 2001;96:1581-6.
               91.  Villa E, Camma C, Marietta M, Luongo M, Critelli R, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in
                   patients with advanced cirrhosis. Gastroenterology 2012;143:1253-60.e4.
               92.  Valentin N, Korrapati P, Constantino J, Young A, Weisberg I. The role of transjugular intrahepatic portosystemic shunt in the management
                   of portal vein thrombosis: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2018;30:1187-93.
               93.  Romualdi E, Ageno W. Investigational factor Xa inhibitors for thrombosis and acute coronary syndromes. Expert Opin Investig Drugs
                   2011;20:495-505.
               94.  Millan M, Caicedo LA, Villegas JI, Serrano O, Caicedo L, et al. Case report of cadaveric kidney transplantation with renal-portal venous
                   drainage: a feasible way for a venous drainage in a complex generalized thrombosed vessels setting. Int J Surg Case Rep 2016;28:192-5.
               95.  Lai W, Lu SC, Li GY, Li CY, Wu JS, et al. Anticoagulation therapy prevents portal-splenic vein thrombosis after splenectomy with
                   gastroesophageal devascularization. World J Gastroenterol 2012;18:3443-50.
               96.  Delgado MG, Seijo S, Yepes I, Achecar L, Catalina MV, et al. Efficacy and safety of anticoagulation on patients with cirrhosis and portal
                   vein thrombosis. Clin Gastroenterol Hepatol 2012;10:776-83.
               97.  Cheng Z, Yu F, Tian J, Guo P, Li J, et al. A comparative study of two anti-coagulation plans on the prevention of PVST after laparoscopic
   50   51   52   53   54   55   56   57   58   59   60